Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Manipulation of a transcriptional repressor promotes expression of protective fetal globin genes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the degree of γ -globin induction is substantially less than that seen with BCL11A de fi ciency (8).”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
In the citing paper
“Reducing bcl11a expression in transgenic sickle mice derepressed g-globin genes.17,18”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [18]
In the citing paper
“However, deletion of BCL11A in mouse results in much greater increases (31.2- to 232.9-fold) of embryonic globin genes in de fi nitive fetal liver and bone marrow erythroid cells (Fig. 4 C and E ) (8)”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
In the citing paper
“Most importantly, inactivation of BCL11A alone is suf fi cient to ameliorate the hematologic and pathologic defects associated with SCD through high-level HbF induction in humanized mouse models (8).”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
In the citing paper
“DNA methylation plays an important role in globin gene expression, and DNA demethylating agents have been shown to induce HbF expression in various model systems and patients (8, 17, 18).”
From Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A (2013) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.
Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.-W., Meissner, A., Cassady, J. P., Beard, C., Brambrink, T., Wu, L.-C., Townes, T. M., et al. (2007) · Science · doi:10.1126/science.1152092 · Cited by 1,202
Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
Self-citationA Specific Chemical Difference Between the Globins of Normal Human and Sickle-Cell Anæmia Hæmoglobin
INGRAM, V. M. (1956) · Nature · doi:10.1038/178792a0 · Cited by 896
Direct inhibition of the NOTCH transcription factor complex
Moellering, R. E., Cornejo, M., Davis, T. N., Bianco, C. D., Aster, J. C., Blacklow, S. C., Kung, A. L., Gilliland, D. G., Verdine, G. L., & Bradner, J. E. (2009) · Nature · doi:10.1038/nature08543 · Cited by 752
Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910.
Jb, H. (2001) · PubMed Central · Cited by 676
Cited by
Therapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886
Self-citationAn Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
Self-citationChromothripsis as an on-target consequence of CRISPR–Cas9 genome editing
Leibowitz, M. L., Papathanasiou, S., Doerfler, P. A., Blaine, L. J., Sun, L., Yao, Y., Zhang, C.-Z., Weiss, M. J., & Pellman, D. (2021) · Nature Genetics · doi:10.1038/s41588-021-00838-7 · Cited by 583
“Specifically, NHEJ-mediated disruption of DNA regions that are required for the repression of fetal hemoglobin (HbF) expression in red blood cell progenitors can alleviate the symptoms of severe β -hemoglobinopathies 3–6 .”
Fetal hemoglobin in sickle cell anemia
Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553
Genetics of Human Cardiovascular Disease
Kathiresan, S., & Srivastava, D. (2012) · Cell · doi:10.1016/j.cell.2012.03.001 · Cited by 496
“…of HbF expression in erythroid cells (Sankaran et al., 2008, 2009; Xu et al., 2010) and demonstrated that inactivation of BCL11A in a mouse model of sickle cell disease leads to pancellular induction of HbF and corrected the hematologic and pathologic defects of the disease (Xu et al., 2011).”
Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9
Mandal, P. K., Ferreira, L. M. R., Collins, R., Meissner, T. B., Boutwell, C. L., Friesen, M., Vrbanac, V., Garrison, B. S., Stortchevoi, A., Bryder, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.10.004 · Cited by 475
“For example, recent studies have identified regulatory regions that control expression of fetal hemoglobin (Bauer et al., 2013), which if deleted increase fetal globin expression in cells otherwise restricted to expressing adult β-globin (Bauer et al., 2013; Xu et al., 2011).”
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
Esrick, E. B., Lehmann, L. E., Biffi, A., Achebe, M., Brendel, C., Ciuculescu, M. F., Daley, H., MacKinnon, B., Morris, E., Federico, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029392 · Cited by 449
Self-citationTranscription factors LRF and BCL11A independently repress expression of fetal hemoglobin
Masuda, T., Wang, X., Maeda, M., Canver, M. C., Sher, F., Funnell, A. P. W., Fisher, C., Suciu, M., Martyn, G. E., Norton, L. J., et al. (2016) · Science · doi:10.1126/science.aad3312 · Cited by 373
Self-citationThe switch from fetal to adult hemoglobin.
Sankaran, V. G., & Orkin, S. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011643 · Cited by 333
“Such a synergistic effect was observed when 5-azacytidine treatment was used in a BCL11A knockout mouse model (Xu et al. 2011), suggesting that such strategies could potentially also be effective in humans.”
BackgroundInfluentialSelf-citationNon-transfusion-dependent thalassemias
Musallam, K. M., Rivella, S., Vichinsky, E., & Rachmilewitz, E. A. (2013) · Haematologica · doi:10.3324/haematol.2012.066845 · Cited by 326
Enhancer biology and enhanceropathies
Smith, E., & Shilatifard, A. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2784 · Cited by 311
In Situ Capture of Chromatin Interactions by Biotinylated dCas9
Liu, X., Zhang, Y., Chen, Y., Li, M., Zhou, F., Li, K., Cao, H., Ni, M., Liu, Y., Gu, Z., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.003 · Cited by 315
Self-citationMartyn, G. E., Wienert, B., Yang, L., Shah, M., Norton, L. J., Burdach, J., Kurita, R., Nakamura, Y., Pearson, R. C. M., Funnell, A. P. W., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0085-0 · Cited by 300
Anemia: progress in molecular mechanisms and therapies
Sankaran, V. G., & Weiss, M. J. (2015) · Nature Medicine · doi:10.1038/nm.3814 · Cited by 281
Self-citationFetal hemoglobin in sickle cell anemia: a glass half full?
Steinberg, M. H., Chui, D. H. K., Dover, G. J., Sebastiani, P., & Alsultan, A. (2014) · Blood · doi:10.1182/blood-2013-09-528067 · Cited by 267
“3% in control animals.(26) Whether or not targeting BCL11A or its pathway in humans will result in a pancellular or heterocellular distribution of HbF among erythrocytes is unknown.”
Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing
Li, K., Liu, Y., Cao, H., Zhang, Y., Gu, Z., Liu, X., Yu, A., Kaphle, P., Dickerson, K. E., Ni, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14362-5 · Cited by 251
Self-citationTreating sickle cell disease by targeting HbS polymerization
Eaton, W. A., & Bunn, H. F. (2017) · Blood · doi:10.1182/blood-2017-02-765891 · Cited by 255
“One promising approach is the selective inhibition of the transcription factor BC11A, which dramatically increases the expression of g globin.(54,55) Because of the enormous sensitivity of the kinetics of polymerization to the concentration of the HbS homotetramer a2b S 2, the beneficial effect of HbF results primaril…”
BackgroundArora, M. (2013) · Materials and Methods · doi:10.13070/mm.en.3.175 · Cited by 216
Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A
Xu, J., Bauer, D. E., Kerenyi, M. A., Vo, T. D., Hou, S., Hsu, Y.-J., Yao, H., Trowbridge, J. J., Mandel, G., & Orkin, S. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303976110 · Cited by 233
“Previously silenced γ-globin genes can also be reactivated by loss of BCL11A in adult animals (8).”
BackgroundMethodSelf-citationComparison of DNA methylation profiles in human fetal and adult red blood cell progenitors
Lessard, S., Beaudoin, M., Benkirane, K., & Lettre, G. (2015) · Genome Medicine · doi:10.1186/s13073-014-0122-2 · Cited by 215
“In a mouse model, inactivation of BCL11A and treatment with demethylating 5-aza-2’-deoxycytidine has a synergistic effect on HbF production [21].”
BackgroundMethodInfluentialPiel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00096-0 · Cited by 177
Self-citationXu, J., Shao, Z., Glass, K., Bauer, D. E., Pinello, L., Van Handel, B., Hou, S., Stamatoyannopoulos, J. A., Mikkola, H. K. A., Yuan, G.-C., et al. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.09.003 · Cited by 200
Self-citationAdvances in understanding erythropoiesis: evolving perspectives
Nandakumar, S. K., Ulirsch, J. C., & Sankaran, V. G. (2016) · British Journal of Haematology · doi:10.1111/bjh.13938 · Cited by 172
Self-citationGenetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease
Hoban, M. D., Orkin, S. H., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2015-09-618587 · Cited by 194
“Erythroid-specific loss of BCL11A in mouse models of SCD is sufficient to reverse the hematologic and pathologic manifestations of disease, thereby validating BCL11A as a therapeutic target.(94) As BCL11A also has important roles in B-cell and dendritic cell development, its complete knockout in HSCs could impair prod…”
BackgroundSelf-citationPathophysiology and Clinical Manifestations of the -Thalassemias
Nienhuis, A. W., & Nathan, D. G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011726 · Cited by 180
“Experimental evidence shows correction of sickle cell disease in a mouse model by suppression of Bcllla (Xu et al. 2011).”
BackgroundSickle Cell Disease: New Opportunities and Challenges in Africa
Makani, J., Ofori-Acquah, S. F., Nnodu, O., Wonkam, A., & Ohene-Frempong, K. (2013) · The Scientific World Journal · doi:10.1155/2013/193252 · Cited by 175
“Hindawi Publishing Corporation The Scientific World Journal Volume 2013, Article ID 193252, 16 pages http://dx.doi.org/10.1155/2013/193252 Review Article Sickle Cell Disease: New Opportunities and Challenges in Africa J. Makani,1,2 S. F. Ofori-Acquah,3,4 O. Nnodu,5 A. Wonkam,6,7 and K. Ohene-Frempong8 1 Department of…”
BackgroundInfluentialReawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders
Bauer, D. E., Kamran, S. C., & Orkin, S. H. (2012) · Blood · doi:10.1182/blood-2012-06-292078 · Cited by 177
Self-citationRegulation of mitochondrial biogenesis in erythropoiesis by mTORC1-mediated protein translation
Liu, X., Zhang, Y., Ni, M., Cao, H., Signer, R. A. J., Li, D., Li, M., Gu, Z., Hu, Z., Dickerson, K. E., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3527 · Cited by 171
Self-citationSickle Cell Anemia and Its Phenotypes
Williams, T., & Thein, S. L. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021320 · Cited by 201
“Downstream studies in primary human erythroid progenitor cells and transgenic mice have demonstrated that BCL11A acts as a repressor of γ-globin gene expression (169, 222).”
BackgroundLoss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
Gu, Z., Liu, Y., Cai, F., Patrick, M., Zmajkovic, J., Cao, H., Zhang, Y., Tasdogan, A., Chen, M., Qi, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0152 · Cited by 173
Self-citationLysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction
Shi, L., Cui, S., Engel, J. D., & Tanabe, O. (2013) · Nature Medicine · doi:10.1038/nm.3101 · Cited by 172
BCL11A Haploinsufficiency Causes an Intellectual Disability Syndrome and Dysregulates Transcription
Dias, C., Estruch, S. B., Graham, S. A., McRae, J., Sawiak, S. J., Hurst, J. A., Joss, S. K., Holder, S. E., Morton, J. E. V., Turner, C., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.05.030 · Cited by 163
“On the other, it raises concern with regards to the inactivation of BCL11A as a target for hemoglobinopathies.(88) Given the broad transcriptional effects of reducing BCL11A dose in the brain, any therapeutic, even if restricted to erythroid lineages, would require caution.”
BackgroundLineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.
Brendel, C., Guda, S., Renella, R., Bauer, D. E., Canver, M. C., Kim, Y.-J., Heeney, M. M., Klatt, D., Fogel, J., Milsom, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87885 · Cited by 167
Self-citationGene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β A(T87Q) - Globin Gene
Negre, O., Eggimann, A.-V., Beuzard, Y., Ribeil, J.-A., Bourget, P., Borwornpinyo, S., Hongeng, S., Hacein-Bey, S., Cavazzana, M., Leboulch, P., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.007 · Cited by 159
Chang, K.-H., Smith, S. E., Sullivan, T., Chen, K., Zhou, Q., West, J. A., Liu, M., Liu, Y., Vieira, B. F., Sun, C., et al. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.009 · Cited by 155
“In any case, suboptimal engraftment of exon 2-edited CD34+ cells and reduced erythroid enucleation suggest that genome editing of the coding region of BCL11A is not a sustainable strategy for SCD.”
BackgroundInfluentialDomain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells
Grevet, J. D., Lan, X., Hamagami, N., Edwards, C. R., Sankaranarayanan, L., Ji, X., Bhardwaj, S. K., Face, C. J., Posocco, D. F., Abdulmalik, O., et al. (2018) · Science · doi:10.1126/science.aao0932 · Cited by 153
Progress and promise in understanding the genetic basis of common diseases
Price, A. L., Spencer, C. C. A., & Donnelly, P. (2015) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2015.1684 · Cited by 147
Bauer, D. E., & Orkin, S. H. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.08.001 · Cited by 143
“Current Opinion in Genetics & Development 2015, 33:62–70 deacetylase, and LSD1 demethylase, are much more effective in the absence of BCL11A [21 ,24].”
BackgroundSelf-citationLee, Y. T., de Vasconcellos, J. F., Yuan, J., Byrnes, C., Noh, S.-J., Meier, E. R., Kim, K. S., Rabel, A., Kaushal, M., Muljo, S. A., et al. (2013) · Blood · doi:10.1182/blood-2012-12-472308 · Cited by 142
“The role of BCL11A in globin gene regulation was confirmed experimentally using human erythroblasts(11) and geneticallymodified mice.(48) Because neither BCL11A knockdown nor direct let-7 suppression had effects on LIN28A or LIN28B expression, our data suggest that LIN28B affects the expression of HbF primarily by tar…”
BackgroundFetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
Sickle Cell Disease: Advances in Treatment
Gardner, R. V. (2018) · Ochsner Journal · doi:10.31486/toj.18.0076 · Cited by 144
Gene Therapy for β-Hemoglobinopathies
Cavazzana, M., Antoniani, C., & Miccio, A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.024 · Cited by 124
MicroRNA-486-3p Regulates γ-Globin Expression in Human Erythroid Cells by Directly Modulating BCL11A
Lulli, V., Romania, P., Morsilli, O., Cianciulli, P., Gabbianelli, M., Testa, U., Giuliani, A., & Marziali, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060436 · Cited by 133
“These observations suggest that besides BCL11A, dispensable for red cell production and proper maturation of erythroid cells [53], miR486-3p might regulate relevant proteins involved in erythropoiesis.”
BackgroundGene therapy for sickle cell disease: An update
Demirci, S., Uchida, N., & Tisdale, J. F. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.04.003 · Cited by 165
“in vivo [77], showing the importance of this gene as a potential target for further clinical studies.”
BackgroundRivella, S. (2015) · Haematologica · doi:10.3324/haematol.2014.114827 · Cited by 139
“potential therapeutic effects not only in b-thalassemia, but also in sickle cell anemia.(37-79) Transcription factors such as GATA binding protein 1 (GATA1), Friend of Gata1 (FOG1), B-cell lymphoma/leukemia 11A (BCL11A), Krueppel-like factor”
BackgroundmiRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction
Guda, S., Brendel, C., Renella, R., Du, P., Bauer, D. E., Canver, M. C., Grenier, J. K., Grimson, A., Kamran, S. C., Thornton, J. E., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.113 · Cited by 126
Self-citationBcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype
Luc, S., Huang, J., McEldoon, J. L., Somuncular, E., Li, D., Rhodes, C., Mamoor, S., Hou, S., Xu, J., & Orkin, S. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.064 · Cited by 122
“Subsequent studies demonstrated that BCL11A is expressed in adult definitive erythroid cells and acts as a transcriptional repressor of human fetal and mouse embryonic b-like globin genes (Bauer et al., 2013; Sankaran et al., 2008, 2009; Xu et al., 2011).”
BackgroundSelf-citationEmerging genetic therapy for sickle cell disease
Orkin, S. H., & Bauer, D. E. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041817-125507 · Cited by 119
Self-citationEx vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications
Li, Y., Glass, Z., Huang, M., Chen, Z., & Xu, Q. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119711 · Cited by 128
Wake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies
Wienert, B., Martyn, G. E., Funnell, A. P. W., Quinlan, K. G. R., & Crossley, M. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.09.004 · Cited by 115
Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies
Vinjamur, D. S., Bauer, D. E., & Orkin, S. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15038 · Cited by 114
“Application of various HDR-based gene-editing strategies to correct the SCD mutation in patient cells ex vivo has achieved up to 30–50% successfully corrected alleles in vitro, although when edited cells were xenotransplanted, at best about 6% corrected alleles were found in engrafting human cells in mouse bone marrow…”
BackgroundSelf-citationRational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis
Sher, F., Hossain, M., Seruggia, D., Schoonenberg, V. A. C., Yao, Q., Cifani, P., Dassama, L. M. K., Cole, M. A., Ren, C., Vinjamur, D. S., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0453-4 · Cited by 111
Self-citationFetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies
Lettre, G., & Bauer, D. E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01341-0 · Cited by 104
Mi2β-mediated silencing of the fetal γ-globin gene in adult erythroid cells
Amaya, M., Desai, M., Gnanapragasam, M. N., Wang, S. Z., Zu Zhu, S., Williams, D. C., & Ginder, G. D. (2013) · Blood · doi:10.1182/blood-2012-11-466227 · Cited by 102
“Knockout of BCL11A in a humanized sickle cell transgenic mouse model greatly ameliorates the sickle cell disease phenotype.(15) Epigenetic mechanisms, including DNA methylation and histone modifications, also play an important role in developmental globin gene silencing,(6,16-20) and inhibitors of DNA methylation indu…”
BackgroundSickle Cell Disease in Children
Meier, E. R., & Miller, J. L. (2012) · Drugs · doi:10.2165/11632890-000000000-00000 · Cited by 117
“Murine BCL11A knock down models consistently have higher levels of HbF than the wild type animals, and a recent study in BCL11A knock out mice demonstrated improved SCD phenotype and haematological findings.([91]) Targeting BCL11A could potentially increase HbF levels in haemoglobinopathy patients, which could lead to…”
BackgroundChapin, J. C., & Giardina, P. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00040-8 · Cited by 108
KLF1 drives the expression of fetal hemoglobin in British HPFH
Wienert, B., Martyn, G. E., Kurita, R., Nakamura, Y., Quinlan, K. G. R., & Crossley, M. (2017) · Blood · doi:10.1182/blood-2017-02-767400 · Cited by 93
Cui, S., Lim, K.-C., Shi, L., Lee, M., Jearawiriyapaisarn, N., Myers, G., Campbell, A., Harro, D., Iwase, S., Trievel, R. C., et al. (2015) · Blood · doi:10.1182/blood-2015-02-626259 · Cited by 98
“Themagnitude of g-globin induction in the SCD mouse by RN-1 is comparable with that previously reported for decitabine orHU in transgenicmousemodels.(50,51) Notably, RN-1 treatment robustly increased the expression of murine embryonic ey- and bh1-globin genes (Figure 1E-F).”
MethodNuclease-mediated gene editing by homologous recombination of the human globin locus
Voit, R. A., Hendel, A., Pruett-Miller, S. M., & Porteus, M. H. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt947 · Cited by 91
Wonkam, A., Bitoungui, V. J. N., Vorster, A. A., Ramesar, R., Cooper, R., Tayo, B. O., Lettre, G., & Ngogang, J. Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092506 · Cited by 92
“Moreover, other investigators have recently demonstrated that inactivation of BCL11A in an SCD transgenic mouse model completely eliminates the hematologic and pathologic defects associated with SCD through induction of high-level pancellular HbF [18].”
BackgroundLi, C., Psatha, N., Sova, P., Gil, S., Wang, H., Kim, J., Kulkarni, C., Valensisi, C., Hawkins, R. D., Stamatoyannopoulos, G., et al. (2018) · Blood · doi:10.1182/blood-2018-03-838540 · Cited by 87
Breda, L., Motta, I., Lourenco, S., Gemmo, C., Deng, W., Rupon, J. W., Abdulmalik, O. Y., Manwani, D., Blobel, G. A., & Rivella, S. (2016) · Blood · doi:10.1182/blood-2016-01-691089 · Cited by 83
Recent trends in the gene therapy of β-thalassemia
Gambari, R., Finotti, A., Breda, L., Lederer, C. W., Bianchi, N., Zuccato, C., Klenathous, M., & Rivella, S. (2015) · Journal of Blood Medicine · doi:10.2147/jbm.s46256 · Cited by 106
Genetic association studies in β-hemoglobinopathies
Thein, S. L. (2013) · Hematology · doi:10.1182/asheducation-2013.1.354 · Cited by 96
Sahel, D. K., Vora, L. K., Saraswat, A. L., Sharma, S., Monpara, J. D., D’souza, A. A., Mishra, D., Tryphena, K. P., Kawakita, S., Khan, S. U., et al. (2023) · Advanced Science · doi:10.1002/advs.202207512 · Cited by 88
Zhang, D., Wang, W.-T., Xiong, J., Xie, X.-M., Cui, S.-S., Zhao, Z.-G., Li, M. J., Zhang, Z., Hao, D., Zhao, X., et al. (2017) · Scientific Reports · doi:10.1038/srep46204 · Cited by 75
BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases
Yin, J., Xie, X., Ye, Y., Wang, L., & Che, F. (2019) · Bioscience Reports · doi:10.1042/bsr20190604 · Cited by 77
Woodworth, M. B., Greig, L. C., Liu, K. X., Ippolito, G. C., Tucker, H. O., & Macklis, J. D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.064 · Cited by 79
“In the hematopoietic system, Ctip1 controls the development of B cells (Lee et al., 2013; Liu et al., 2006; 2003) and regulates switching between fetal and adult forms of hemoglobin (Bauer et al., 2013; Canver et al., 2015; Sankaran et al., 2008; 2009; Xu et al., 2011).”
Self-citationAngelicin—A Furocoumarin Compound With Vast Biological Potential
Mahendra, C. K., Tan, L. T., Lee, W.-L., Yap, W. H., Pusparajah, P., Low, L. E., Tang, S. Y., Chan, K., Lee, L., & Goh, B. H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00366 · Cited by 78
Cure for thalassemia major – from allogeneic hematopoietic stem cell transplantation to gene therapy
Srivastava, A., & Velayudhan, S. R. (2016) · Haematologica · doi:10.3324/haematol.2015.141200 · Cited by 81
Brendel, C., Negre, O., Rothe, M., Guda, S., Parsons, G., Harris, C., McGuinness, M., Abriss, D., Tsytsykova, A., Klatt, D., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.015 · Cited by 72
“High HbF induction was seen in colonies with only a single vector integrant ( 30% increase in HbF over mock control per VCN), which is indicative of the potency of the BCHBB694 LVV vector, and colonies containing higher VCNs showed additional moderate but non-linear increase in HbF.”
BackgroundSelf-citationKhosravi, M. A., Abbasalipour, M., Concordet, J., Berg, J. V., Zeinali, S., Arashkia, A., Azadmanesh, K., Buch, T., & Karimipoor, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.04.042 · Cited by 76
Funnell, A. P. W., Prontera, P., Ottaviani, V., Piccione, M., Giambona, A., Maggio, A., Ciaffoni, F., Stehling-Sun, S., Marra, M., Masiello, F., et al. (2015) · Blood · doi:10.1182/blood-2015-04-638528 · Cited by 77
“Moreover, BCL11A knockdown in primary human erythroid cells results in increased fetal hemoglobin (HbF),(6)whereas conditional knockout in adult sickle cell disease transgenic mice leads to reactivation of g-globin and amelioration of symptoms.(7) Erythroid-specific abrogation of BCL11A has thus been pursued as an att…”
BackgroundTrakarnsanga, K., Wilson, M. C., Lau, W. W. Y., Singleton, B. K., Parsons, S. F., Sakuntanaga, P., Kurita, R., Nakamura, Y., Anstee, D. J., & Frayne, J. (2014) · Haematologica · doi:10.3324/haematol.2014.110155 · Cited by 76
Three fingers on the switch: Krüppel-like factor 1 regulation of γ-globin to β-globin gene switching
Tallack, M. R., & Perkins, A. C. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32835f59ba · Cited by 80
Li, C., Psatha, N., Gil, S., Wang, H., Papayannopoulou, T., & Lieber, A. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.008 · Cited by 71
Greig, L. C., Woodworth, M. B., Greppi, C., & Macklis, J. D. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.008 · Cited by 73
“Ctip1 has been most extensively studied in the hematopoietic system, where it controls specification of Bcells (Liu et al., 2003), and regulates the developmental switch from ɣ-globin to β-globin in red blood cells (Sankaran et al., 2008; Sankaran et al., 2009; Xu et al., 2011; Bauer et al., 2013).”
Regulation of the fetal hemoglobin silencing factor BCL11A
Basak, A., & Sankaran, V. G. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13024 · Cited by 70
Self-citationErythro-megakaryocytic transcription factors associated with hereditary anemia
Crispino, J. D., & Weiss, M. J. (2014) · Blood · doi:10.1182/blood-2014-01-453167 · Cited by 69
“Several studies suggest that inhibition of human BCL11A (through KLF1dependent or -independent mechanisms) can de-repress g globin transcription and thereby alleviate the clinical manifestations of some human hemoglobinopathies, including sickle cell anemia and b-thalassemia.(67,68)”
BackgroundFetal Globin Gene Repressors as Drug Targets for Molecular Therapies To Treat the β-Globinopathies
Suzuki, M., Yamamoto, M. P., & Engel, J. D. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00714-14 · Cited by 72
“Bcl11a-null mutant mice and erythroid cell-specific Bcl11a knockout mice both exhibited an HPFH phenotype (87, 88).”
BackgroundGene Therapy for Hemoglobinopathies
Chandrakasan, S., & Malik, P. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.12.003 · Cited by 74
Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 68
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
“multiplexed Cas9 editing at three target sites has been investigated using electroporation for delivery in preclinical studies to decrease T cell immunogenicity and improve antitumor recognition [167,168].”
BackgroundCustomizing the genome as therapy for the β-hemoglobinopathies.
Canver, M. C., & Orkin, S. H. (2016) · Blood · doi:10.1182/blood-2016-01-678128 · Cited by 61
Self-citationBenitez, C. M., Qu, K., Sugiyama, T., Pauerstein, P. T., Liu, Y., Tsai, J., Gu, X., Ghodasara, A., Arda, H. E., Zhang, J., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004645 · Cited by 56
“Prior studies had revealed crucial roles for Bcl11a in regulating blood development [69] [53] and diseases [70] [71], and for Runx1t1 in midgut development [51] and neoplasias of blood, lung and breast [58] [59].”
BackgroundGenetic Basis and Genetic Modifiers of β-Thalassemia and Sickle Cell Disease
Thein, S. L. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_2 · Cited by 70
Ma, Y., Liu, S., Gao, J., Chen, C., Zhang, X., Yuan, H., Chen, Z., Yin, X., Sun, C., Mao, Y., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2020.12.019 · Cited by 66
Self-citationPule, G. D., Mowla, S., Novitzky, N., & Wonkam, A. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0092-7 · Cited by 62
“Closer to hemoglobinopathies, several miRNAs have been associated with specific phenotypes or key signalling pathways in SCD; miR-15a and miR16-1 with hereditary persistence of HbF [53], miR-148a with DNMT-1 [72], miR-144 and tolerance of oxidative stress and anemia severity [52], a mouse model showing the correction…”
Li, G., Diogo, D., Wu, D., Spoonamore, J., Dancik, V., Franke, L., Kurreeman, F., Rossin, E. J., Duclos, G., Hartland, C., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003487 · Cited by 55
“Based on these data, together with data from animal models [55], repressors of BCL11A are under development for the treatment of sickle cell disease [56].”
MethodCRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease
Demirci, S., Leonard, A. K., Essawi, K., & Tisdale, J. F. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.010 · Cited by 61
Development of gene therapy for blood disorders: an update
Nienhuis, A. W. (2013) · Blood · doi:10.1182/blood-2013-04-453209 · Cited by 61
“Genetic deletion of BCL11A has been used to correct sickle cell disease in adult mice by interference with fetal hemoglobin silencing.(93) In addition, therapeutic levels of BLOOD, 29 AUGUST 2013 x VOLUME 122, NUMBER 9 GENE THERAPY FOR BLOOD DISORDERS 1561 For personal use only.”
MethodGene therapy for hemoglobinopathies: progress and challenges
Dong, A., Rivella, S., & Breda, L. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.011 · Cited by 60
“More recently, targeted reactivation of HbF induced by BCL11A repression was proven successful in correcting the phenotype of transgenic knock out mice, which express exclusively human sickle hemoglobin.(72) Altogether these studies showed new insights in translating HbF silencing into mechanism-based, improved therap…”
BackgroundFlores, C., Mojadidi, M., Phillips, J., Kuo, C. Y., Lai, S. Y., Lill, G. R., Cooper, A. R., Kaufman, M. L., Urbinati, F., Wang, X., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.52 · Cited by 62
Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies
Payen, E., & Leboulch, P. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.276.3807841 · Cited by 59
Erythropoiesis and globin switching in compound Klf1::Bcl11a mutant mice
Esteghamat, F., Gillemans, N., Bilic, I., van den Akker, E., Cantù, I., van Gent, T., Klingmüller, U., van Lom, K., von Lindern, M., Grosveld, F., et al. (2013) · Blood · doi:10.1182/blood-2012-06-434530 · Cited by 51
MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell disease
Li, Y., Zhu, X., Ward, C. M., Starlard‐Davenport, A., Takezaki, M., Berry, A., Ward, A., Wilder, C., Neunert, C. E., Kutlar, A., et al. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.11.002 · Cited by 56
“Subsequent gene knockout confirmed a major repressor role of BCL11A in γ-globin gene silencing during hemoglobin switching [10] through KLF1 activation [11,12] and interaction with the corepressor SOX6 [13,14].”
BackgroundGenetic modifiers of fetal haemoglobin in sickle cell disease
Menzel, S., & Thein, S. L. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0370-8 · Cited by 50
Strict in vivo specificity of the Bcl11a erythroid enhancer
Smith, E. C., Luc, S., Croney, D. M., Woodworth, M. B., Greig, L. C., Fujiwara, Y., Nguyen, M., Sher, F., Macklis, J. D., Bauer, D. E., et al. (2016) · Blood · doi:10.1182/blood-2016-08-736249 · Cited by 52
Self-citationRegulating the Regulators: The Role of Histone Deacetylase 1 (HDAC1) in Erythropoiesis
Kim, M. Y., Yan, B., Huang, S., & Qiu, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228460 · Cited by 52
Metadata
- Authors
- Xu, J., Peng, C., Sankaran, V. G., Shao, Z., Esrick, E. B., Chong, B. G., Ippolito, G. C., Fujiwara, Y., Ebert, B. L., Tucker, P. W., & Orkin, S. H.
- Affiliations
- Boston Children's Hospital (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- The University of Texas at Austin (US)
- Corresponding author
- Peng, Cong
- Sankaran, Vijay G.
- Orkin, Stuart H.
- ORCID
- Venue
- Science
- Published
- 2011-11-18
- Volume
- 334
- Issue
- 6058
- Pages
- 993-996
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3746545
- OpenAlex
- W2033380734
- Cited by
- 326
- References
- 45
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 16 · 2023: 13 · 2022: 18 · 2021: 20 · 2020: 22 · 2019: 18 · 2018: 25 · 2017: 24 · 2016: 42 · 2015: 26 · 2014: 23 · 2013: 32 · 2012: 19
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (T32CA009172)
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK093543)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- sickle cell disease, fetal hemoglobin, BCL11A, beta-thalassemia, transgenic mice, therapeutic target, erythropoiesis
- MeSH terms
- Anemia, Sickle Cell, Animals, Carrier Proteins, DNA-Binding Proteins, Embryo, Mammalian, Fetal Hemoglobin, Gene Expression Regulation, Histones, Humans, Mice, Transgenic, Nuclear Proteins, Repressor Proteins, Mice, Knockout, DNA Methylation, Gene Silencing, Erythroid Cells, Epigenesis, Genetic, Mice, gamma-Globins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.